Related references
Note: Only part of the references are listed.European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines
J. Alfred Witjes et al.
EUROPEAN UROLOGY (2021)
Curcumin: A therapeutic strategy for colorectal cancer?
Vicenc Ruiz de Porras et al.
SEMINARS IN CANCER BIOLOGY (2021)
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
Thomas Powles et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Cancer drug resistance induced by EMT: novel therapeutic strategies
Javier De las Rivas et al.
ARCHIVES OF TOXICOLOGY (2021)
Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial
Michiel S. van der Heijden et al.
EUROPEAN UROLOGY (2021)
Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment
Vicenc Ruiz de Porras et al.
EUROPEAN UROLOGY (2021)
Curcumin reverses hepatic epithelial mesenchymal transition induced by trichloroethylene by inhibiting IL-6R/STAT3
Weiya Cao et al.
TOXICOLOGY MECHANISMS AND METHODS (2021)
Role of JAK/STAT3 Signaling in the Regulation of Metastasis, the Transition of Cancer Stem Cells, and Chemoresistance of Cancer by Epithelial-Mesenchymal Transition
Wook Jin
CELLS (2020)
Final Overall Survival Analysis of the SOGUG Phase 2 MAJA Study: Maintenance Vinflunine Versus Best Supportive Care After First-Line Chemotherapy in Advanced Urothelial Carcinoma
Joaquim Bellmunt Molins et al.
CLINICAL GENITOURINARY CANCER (2020)
Curcumin-A Viable Agent for Better Bladder Cancer Treatment
Jochen Rutz et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
Thomas Powles et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Role of Transmembrane 4 L Six Family 1 in the Development and Progression of Cancer
Fangmei Fu et al.
FRONTIERS IN MOLECULAR BIOSCIENCES (2020)
TM4SF1 promotes EMT and cancer stemness via the Wnt/β-catenin/SOX2 pathway in colorectal cancer
Qiang Tang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2020)
The Challenge of Managing Bladder Cancer and Upper Tract Urothelial Carcinoma: A Review with Treatment Recommendations from the Spanish Oncology Genitourinary Group (SOGUG)
Albert Font et al.
TARGETED ONCOLOGY (2019)
Curcumin: a potent agent to reverse epithelial-to-mesenchymal transition
Afsane Bahrami et al.
CELLULAR ONCOLOGY (2019)
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
Y. Loriot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Transmembrane-4 L-six family member-1 (TM4SF1) promotes non-small cell lung cancer proliferation, invasion and chemo-resistance through regulating the DDR1/Akt/ERK-mTOR axis
Lin Ye et al.
RESPIRATORY RESEARCH (2019)
TM4SF1 regulates apoptosis, cell cycle and ROS metabolism via the PPARγ-SIRT1 feedback loop in human bladder cancer cells
Rui Cao et al.
CANCER LETTERS (2018)
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
Thomas Powles et al.
LANCET (2018)
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
Manish R. Patel et al.
LANCET ONCOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
TM4SF1 promotes the self-renewal of esophageal cancer stem-like cells and is regulated by miR-141
Lei Xue et al.
ONCOTARGET (2017)
Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial
Jesus Garcia-Donas et al.
LANCET ONCOLOGY (2017)
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
Padmanee Sharma et al.
LANCET ONCOLOGY (2017)
EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
Tsukasa Shibue et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
J. Bellmunt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Curcumin inhibits bladder cancer progression via regulation of β-catenin expression
Jing Shi et al.
TUMOR BIOLOGY (2017)
Reversion of epithelial-mesenchymal transition by a novel agent DZ-50 via IGF binding protein-3 in prostate cancer cells
Zheng Cao et al.
ONCOTARGET (2017)
The Use of Systemic Treatment in the Maintenance of Patients with Non-Small Cell Lung Cancer: A Systematic Review
Swati Kulkarni et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Jonathan E. Rosenberg et al.
LANCET (2016)
Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer
Bowen Du et al.
MOLECULES (2016)
Metastatic Bladder Cancer: Second-Line Treatment and Recommendations of the Genitourinary Tumor Division of the Galician Oncologic Society (SOG-GU)
Jorge Garcia et al.
CURRENT ONCOLOGY REPORTS (2016)
Meta-analysis comparing maintenance strategies with continuous therapy and complete chemotherapy-free interval strategies in the treatment of metastatic colorectal cancer
Lei Zhao et al.
ONCOTARGET (2016)
Curcumin potentiates antitumor activity of cisplatin in bladder cancer cell lines via ROS-mediated activation of ERK1/2
Bong Hee Park et al.
ONCOTARGET (2016)
Curcumin mediates oxaliplatinacquired resistance reversion in colorectal cancer cell lines through modulation of CXC-Chemokine/NF-κB signalling pathway
Vicenc Ruiz de Porras et al.
SCIENTIFIC REPORTS (2016)
limma powers differential expression analyses for RNA-sequencing and microarray studies
Matthew E. Ritchie et al.
NUCLEIC ACIDS RESEARCH (2015)
Role of the microtubule-targeting drug vinflunine on cell-cell adhesions in bladder epithelial tumour cells
Luis A Aparicio et al.
BMC CANCER (2014)
Epithelial-to-Mesenchymal Transition Mediates Docetaxel Resistance and High Risk of Relapse in Prostate Cancer
Mercedes Marin-Aguilera et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Molecular mechanisms of epithelial-mesenchymal transition
Samy Lamouille et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2014)
Metformin Inhibits the IL-6-Induced Epithelial-Mesenchymal Transition and Lung Adenocarcinoma Growth and Metastasis
Zhongquan Zhao et al.
PLOS ONE (2014)
Signaling mechanisms of the epithelial-mesenchymal transition
David M. Gonzalez et al.
SCIENCE SIGNALING (2014)
Vinflunine: a new vision that may translate into antiangiogenic and antimetastatic activity
Luis Miguel Anton Aparicio et al.
ANTI-CANCER DRUGS (2012)
Randomized Phase III Study Comparing Paclitaxel/Cisplatin/Gemcitabine and Gemcitabine/Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Cancer Without Prior Systemic Therapy: EORTC Intergroup Study 30987
Joaquim Bellmunt et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Long-term-survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer (vol 17, pg v118, 2006)
Hans von der Maase et al.
ANNALS OF ONCOLOGY (2011)
Insulin-like growth factor-binding protein-3 promotes transforming growth factor-β1-mediated epithelial-to-mesenchymal transition and motility in transformed human esophageal cells
Mitsuteru Natsuizaka et al.
CARCINOGENESIS (2010)
Vinflunine in Platinum-Pretreated Patients With Locally Advanced or Metastatic Urothelial Carcinoma Results of a Large Phase 2 Study
David J. Vaughn et al.
CANCER (2009)
Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer
David J. McConkey et al.
CANCER AND METASTASIS REVIEWS (2009)
The basics of epithelial-mesenchymal transition
Raghu Kalluri et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract
Joaquim Bellmunt et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Pharmacogenomic approach for the identification of novel determinants of acquired resistance to oxaliplatin in colorectal cancer
Anna Martinez-Cardus et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Estimation and assessment of raw copy numbers at the single locus level
H. Bengtsson et al.
BIOINFORMATICS (2008)
Molecular and pathological signatures of epithelial-mesenchymal transitions at the cancer invasion front
Olivier De Wever et al.
HISTOCHEMISTRY AND CELL BIOLOGY (2008)
Antitumor activity of vinflunine: Effector pathways and potential for synergies
Diane Broguer et al.
SEMINARS IN ONCOLOGY (2008)
A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen
S. Culine et al.
BRITISH JOURNAL OF CANCER (2006)
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
A Subramanian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Long-term-survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer
H von der Maase et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Bioconductor: open software development for computational biology and bioinformatics
RC Gentleman et al.
GENOME BIOLOGY (2004)
Exploration, normalization, and summaries of high density oligonucleotide array probe level data
RA Irizarry et al.
BIOSTATISTICS (2003)
Characterization of cell death induced by vinflunine, the most recent Vinca alkaloid in clinical development
A Kruczynski et al.
BRITISH JOURNAL OF CANCER (2002)
Multidrug resistance in cancer: Role of ATP-dependent transporters
MM Gottesman et al.
NATURE REVIEWS CANCER (2002)
Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method
KJ Livak et al.
METHODS (2001)
Vinflunine, the latest Vinca alkaloid in clinical development -: A review of its preclinical anticancer properties
A Kruczynski et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2001)
Share Paper
